Overall_survival_in_non-small_lung_cancer_patients_treated_with_modern_immunotherapy_in_the_first_line_for_advanced_or_metastatic_disease.jpg
Summary
Description Overall survival in non-small lung cancer patients treated with modern immunotherapy in the first line for advanced or metastatic disease.jpg |
English:
Comparison of over survival and hazard ratios (HR) in clinical trials incorporating immunotherapy in the first line for patients with non-small cell lung cancer. The treatment arms without and with immunotherapy are compared in KEYNOTE-024, KEYNOTE-042, KEYNOTE-189, KEYNOTE-407, CHECKMATE-227, CHECKMATE 9LA, IMpower110, IMpower130, and IMpower150.Nasser NJ, Gorenberg M, Agbarya A.Pharmaceuticals 2020, 13(11), 373;
https://doi.org/10.3390/ph13110373
|
Date | |
Source |
First line Immunotherapy for Non-Small Cell Lung Cancer. Nasser NJ, Gorenberg M, Agbarya A. Pharmaceuticals (Basel). 2020 Nov 8;13(11):373 https://doi.org/10.3390/ph13110373 |
Author |
Nicola J. Nasser, Miguel Gorenberg, Abed Agbarya. Pharmaceuticals (Basel). 2020 Nov 8;13(11):373 https://doi.org/10.3390/ph13110373 |
Licensing
This file is licensed under the
Creative Commons
Attribution 4.0 International
license.
-
You are free:
- to share – to copy, distribute and transmit the work
- to remix – to adapt the work
-
Under the following conditions:
- attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.